{
    "nctId": "NCT00002920",
    "briefTitle": "S9630, Medroxyprogesterone in Treating Women With Breast Cancer",
    "officialTitle": "A Randomized Comparison Of Medroxyprogesterone Acetate (MA) And Observation For Prevention Of Endometrial Pathology In Postmenopausal Breast Cancer Patients Treated With Tamoxifen, Phase III",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Endometrial Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 313,
    "primaryOutcomeMeasure": "Endometrial pathologic diagnosis",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* One of the following histologically proven diagnoses:\n\n  * Primary invasive adenocarcinoma of the unilateral or bilateral breast\n\n    * Stage I, IIA, or IIB (T1-3, N0-1, M0)\n    * No recurrent invasive breast cancer\n  * Ductal carcinoma in situ (DCIS)\n  * Lobular carcinoma in situ (LCIS) with microinvasion\n  * Paget's disease of the nipple\n* No sarcoma, lymphoma, or apocrine, adenocystic, or squamous cell cancer of the breast\n* Currently free of breast cancer (no evidence of disease)\n\n  * No evidence of distant disease on chest x-ray or chest CT scan and mammogram of the opposite breast within the past year\n* Prior definitive local treatment of primary lesion (mastectomy or breast-sparing procedure with radiotherapy) and either axillary node or sentinel node biopsy\n\n  * Surgical margins clear of both infiltrating carcinoma (any type) and DCIS\n\n    * No gross or microscopically positive margins except:\n\n      * Invasive cancer or DCIS at the focal margin treated with definitive radiotherapy\n      * Gross or LCIS at the final margin\n  * Biopsy requirement waived for DCIS or LCIS with minimal microinvasion\n* Patients with breast-sparing procedure must have received or be planning to receive radiotherapy at start of tamoxifen treatment\n* No endometrial simple or cystic hyperplasia, proliferative changes, complex (adenomatous) or atypical hyperplasia, or carcinoma\n* Patients must be planning one of the following:\n\n  * Starting adjuvant tamoxifen for five years OR\n  * Started tamoxifen within 28 days prior to study and planning to receive adjuvant tamoxifen for five years\n* Hormone receptor status:\n\n  * Candidate for adjuvant tamoxifen therapy\n\nPATIENT CHARACTERISTICS:\n\nAge:\n\n* Adult\n\nSex:\n\n* Female\n\nMenopausal status:\n\n* Postmenopausal defined as:\n\n  * At least 1 year since last menstrual period\n  * At least 2 months since bilateral oophorectomy prior to breast cancer diagnosis\n  * 4-12 months since last menstrual period and FSH elevated to postmenopausal range\n  * Postmenopausal estrogen therapy and 55 years of age or older\n\nPerformance status:\n\n* Not specified\n\nLife expectancy:\n\n* Not specified\n\nHematopoietic:\n\n* Not specified\n\nHepatic:\n\n* Not specified\n\nRenal:\n\n* Not specified\n\nOther:\n\n* Fertile patients must use effective contraception during and for at least 2 months after study\n* No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or stage I or II cancer currently in complete remission\n* No concurrent nonmalignant-related illness that would preclude study\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy:\n\n* Not specified\n\nChemotherapy:\n\n* Adjuvant chemotherapy allowed\n* No concurrent chemotherapy\n\nEndocrine therapy:\n\n* See Disease Characteristics\n* No prior hormonal treatment for breast cancer (except tamoxifen)\n* No concurrent postmenopausal estrogen therapy\n\nRadiotherapy:\n\n* See Disease Characteristics\n\nSurgery:\n\n* See Disease Characteristics\n* No prior or concurrent hysterectomy\n\nOther:\n\n* No prior or current participation in an adjuvant intergroup trial",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}